Newsletter Subscription

Enter Name and Email

03 September 2012 - Adrian to present at 25th ECNP Congress in Vienna



Adrian Newman-Tancredi Ph.D. will be presenting at the ECNP (European College of Neuropsychopharmacology) meeting in Vienna, Austria, on Monday 15 October 2012. The session will examine recent discoveries that bring renewed interest in serotonin 5-HT1A receptors as promising targets for treatment of psychiatric disorders such as major depression.

Adrian has extensive experience of antipsychotics pharmacology and drug discovery and has presented to a wide variety of audiences. If you are attending the conference, Adrian would be happy to meet and discuss with you: Contact.


Symposium title: "New mechanisms and novel therapeutics: how recent discoveries are opening perspectives for targeting serotonin 5-HT1A receptor function"
Symposium S.11, 09:00 - 10:40,  Hall F1. Co-Chairs: Per Svenningsson (Sweden), Ove Wiborg (Denmark)

1. Paul R. Albert (Canada): Transcriptional dysregulation of 5-HT1A receptors in psychiatric disorders.
2. Justine Masson (France): Brain region-dependent internalisation of 5-HT1A receptors: molecular mechanisms and relevance for antidepressant therapy.
3. Francesc Artigas (Spain): Antidepressant effects elicited by siRNA inactivation of 5-HT1A receptors in rodents: implications for serotonergic circuitry.
4. Adrian Newman-Tancredi (France): 'Biased agonism' at cortical post-synaptic 5-HT1A receptors for improved treatment of depressive disorders.

For full details of the ECNP Congress click here.